Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 12, 2011, Pages 1593-1599

  Nickels, Andrew S ^a   Dimov, Vesselin ^a   Wolf, Raoul ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Allergic conjunctivitis; Allergic rhinitis; Antihistamine; Conjunctival allergen challenge; Mast cell stabilizer; Olopatadine; Pharmacokinetics; Rhinoconjunctivitis

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; FLUTICASONE PROPIONATE; LORATADINE; MOMETASONE FUROATE; OLOPATADINE; PLACEBO; STEROID;

ALLERGIC DISEASE; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BITTER TASTE; BURNING SENSATION; CONJUNCTIVITIS; CONTACT LENS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY EYE; EPISTAXIS; EYELID EDEMA; FOREIGN BODY REACTION; HUMAN; HYPEREMIA; HYPERSENSITIVITY REACTION; KERATITIS; MAXIMUM PLASMA CONCENTRATION; MEDICAL LITERATURE; META ANALYSIS; NONHUMAN; NOSE ULCER; PATIENT COMPLIANCE; PHARYNGITIS; PRACTICE GUIDELINE; RHINITIS; SIDE EFFECT; SKIN TEST; SOMNOLENCE; SORE THROAT; SYSTEMATIC REVIEW; TASTE DISORDER;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, OPHTHALMIC; ADMINISTRATION, ORAL; ANTI-ALLERGIC AGENTS; CLINICAL TRIALS AS TOPIC; CONJUNCTIVITIS; DIBENZOXEPINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; META-ANALYSIS AS TOPIC; RHINITIS;

EID: 81855226430     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.630389     Document Type: Article

References (31)

1. Canonica GW. Treating asthma as an inflammatory disease. Chest 2006;130:21S-8S
2. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122:S1-84
3. Roland PS, Ryan MW, Wall GM. Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother 2010;11:1559-67
4. Patanase nasal spray prescribing information. Alcon, 2009. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/ 021861s002lbl.pdf . FDA approved labeling and prescribing information of intranasal olopatadine 0.6%.
5. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (al-4943a), an effective anti-allergic/ antihistaminic agent. J Ocul Pharmacol Ther 1996;12:389-400
6. Kaise T, Ohmori K, Sakakura Y, et al. The effect of kw-4679, an antiallergic drug, on experimental allergic rhinitis in guinea pigs: Effects on nasal blockage. Jpn J Pharmacol 1995;69:435-8
7. Chu NN, Chen WL, Xu HR, et al. Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy chinese subjects: An open-label study. Clin Drug Investig 2009;29:451-7
8. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 2002;88:379-97
9. Patanol prescribing information. 2007. Available from: http://ecatalog.alcon.com/ pi/Patanol-us-en.pdf . FDA approved labeling and prescribing information of ophthalmic olopatadine 0.1%.
10. Leonardi A, Abelson MB. Doublemasked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003;25:2539-52
11. Kaliner MA, Oppenheimer J, Farrar JR. Comprehensive review of olopatadine: The molecule and its clinical entities. Allergy Asthma Proc 2010;31:112-19
12. Yamamoto H, Yamada T, Kubo S, et al. Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study. Allergy Asthma Proc 2010;31:296-303
13. Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:600-6
14. Ratner PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol 2005;95:474-9
15. Fairchild CJ, Meltzer EO, Roland PS, et al. Comprehensive report of the efficacy, safety, quality of life, and work impact of olopatadine 0.6% and olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2007;28:716-23
16. LaForce CF, Carr W, Tilles SA, et al. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. Allergy Asthma Proc 2010;31:132-40
17. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998;125:797-804
18. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108:84-8
19. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001;23:1272-80
20. Abelson MB, Gomes PJ, Vogelson CT, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: A randomized, double-masked environmental study. Clin Ther 2004;26:1237-48
21. Uchio E. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clin Ophthalmol 2008;2:525-31
22. Vogelson CT, Abelson MB, Pasquine T, et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc 2004;25:69-75
23. Abelson MB, Spangler DL, Epstein AB, et al. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr Eye Res 2007;32:1017-22
24. Abelson MB, Gomes PJ, Vogelson CT, et al. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Curr Med Res Opin 2005;21:683-91
25. Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasalfluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952-7
26. Rosenwasser LJ, Mahr T, Abelson MB, et al. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy Asthma Proc 2008;29:644-53
27. Meltzer EO, Garadi R, Laforce C, et al. Comparative study of sensory attributes of two antihistamine nasal sprays: Olopatadine 0.6% and azelastine 0.1%. Allergy Asthma Proc 2008;29:659-68
28. Pataday prescribing information: 2010. Available from: http://ecatalog.alcon.com/ pi/Pataday-us-en.pdf . FDA approved labeling and prescribing information of ophthalmic olopatadine 0.2%.
29. Dassanayake NL, Carey TC, Owen GR. A laboratory model to determine the uptake and release of olopatadine by soft contact lenses. Acta Ophthalmol Scand Suppl 2000;78:16-17
30. Brodsky M, Berger WE, Butrus S, et al. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model. Eye Contact Lens 2003;29:113-16
31. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:74-81